Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks Consensus Estimate of 58 cents per share. Earnings rose 30% year over year.

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the ...

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (OLMA) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.